Professor Stephen Wiviott

Stephen D. Wiviott, MD, FACC is a graduate of University of Pennsylvania (Mathematics, Magna Cum Laude) and Harvard Medical School (HMS, Honors). He served as a Medicine resident and Chief Medical Resident at Brigham and Women’s Hospital (BWH). Following his medical residency training, he served as a Cardiology fellow at Johns Hopkins Hospital and as a cardiovascular research fellow with the TIMI Study Group, a leading academic CV clinical trials organization. After completing his training, he joined the faculty of the Cardiovascular Division of BWH. He is Associate Professor of Medicine at Harvard Medical School, and a Senior Investigator with TIMI. He attends in the Lown Cardiovascular Intensive Care Unit and general Cardiology service at BWH.

As an investigator, Dr. Wiviott has played important roles in the planning, implementation, and interpretation of multicenter, national, and international clinical trials in acute coronary syndromes including the TRITON-TIMI 38 trial, the major III trial which led to the world-wide regulatory approval of prasugrel, a novel antiplatelet agent. He was the Principal Investigator (PI) of PRINCIPLE-TIMI 44, a study comparing high-dose clopidogrel with prasugrel in patients undergoing PCI, and of the TIMI 38 Coronary Stent Registry. He has also served key roles in trials of secondary prevention of cardiovascular disease as an executive committee member of DAPT and REVEAL, and as global PI of DECLARE – TIMI 58 and CAMELLIA – TIMI 61 assessing CV safety and efficacy of metabolic therapies.  He is the Chairman of the TIMI Clinical Events Committee, and recognized as an expert in clinical event definitions and adjudications.

Building on his trials experience, Dr. Wiviott was appointed Executive Director of the Clinical Trials Office (CTO) for Partners HealthCare in February of 2018. The CTO provides contracting, budgeting, and clinical trial management services for Partners member-hospital investigators and industry sponsors and is tasked with supporting and growing clinical trials research at Partners.

Dr. Wiviott is an author of more than 175 peer-reviewed publications in major medical and cardiovascular journals. He was named in 2014 and 2017 by Thomson Reuters and Clarvate Analytics as one of “The World’s Most Influential Scientific Minds” and in 2016 as a “Highly Cited Researcher,” each recognition inclusive of the top 1% of researchers in Clinical Medicine by citation. He has delivered local, national, and international lectures in the fields of acute coronary syndromes, platelet biology, established and novel antiplatelet agents, diabetes and prevention. Areas of current clinical and research interest include acute coronary syndromes, platelet inhibitors, cholesterol-lowering therapy, cardiovascular effects of diabetes therapies, and secondary prevention of CAD and pragmatic clinical trials